Recent Advances in Thermally Activated Delayed Fluorescent Materials in Type II Photodynamic Therapy

Abstract

Photodynamic therapy (PDT) represents a novel, dual-stage cancer treatment approach that combines light energy and photosensitizers to destroy cancerous and precancerous cells through the generation of radicals (Type I) or singlet oxygen (Type II). Since the early 2010s, PDT has advanced significantly, with the focus shifting toward the exploration of molecules capable of thermally activated delayed fluorescence (TADF) as viable alternatives to traditional metallic complexes and organometallic compounds for producing the necessary active species. TADF molecules exhibit higher energy conversion efficiency, long-lived triplet excitons, tunable photophysical properties, and a small singlet-triplet energy gap, facilitating efficient intersystem crossing and enhanced singlet oxygen generation. As metal-free luminophores, they offer benefits such as reduced health risks, high structural flexibility, and biocompatibility, which can significantly enhance PDT treatment efficacy. Notably, in 2019, a pivotal shift occurred, with researchers concentrating their efforts on identifying and investing in potential molecules specifically for Type II PDT applications. This review presents the innovative use of materials characterized by closely spaced S₁ and T₁ orbitals, crucial for the efficient generation of singlet oxygen in PDT. Exploring these materials opens new avenues for enhancing the efficacy and specificity of PDT, offering promising for future cancer treatments.